Fuji Pharma Co Ltd
TSE:4554

Watchlist Manager
Fuji Pharma Co Ltd Logo
Fuji Pharma Co Ltd
TSE:4554
Watchlist
Price: 1 458 JPY 2.46% Market Closed
Market Cap: 35.4B JPY
Have any thoughts about
Fuji Pharma Co Ltd?
Write Note

Fuji Pharma Co Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Fuji Pharma Co Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Fuji Pharma Co Ltd
TSE:4554
Cash Equivalents
ÂĄ2.7B
CAGR 3-Years
-34%
CAGR 5-Years
-18%
CAGR 10-Years
-10%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash Equivalents
ÂĄ859B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
2%
Daiichi Sankyo Co Ltd
TSE:4568
Cash Equivalents
ÂĄ707.7B
CAGR 3-Years
9%
CAGR 5-Years
19%
CAGR 10-Years
15%
Otsuka Holdings Co Ltd
TSE:4578
Cash Equivalents
ÂĄ515.1B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash Equivalents
ÂĄ462.9B
CAGR 3-Years
34%
CAGR 5-Years
21%
CAGR 10-Years
16%
Astellas Pharma Inc
TSE:4503
Cash Equivalents
ÂĄ302.9B
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
-2%
No Stocks Found

Fuji Pharma Co Ltd
Glance View

Market Cap
35.4B JPY
Industry
Pharmaceuticals

Fuji Pharma Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 1,532 full-time employees. The firm is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.

Intrinsic Value
2 002.38 JPY
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Fuji Pharma Co Ltd's Cash Equivalents?
Cash Equivalents
2.7B JPY

Based on the financial report for Jun 30, 2024, Fuji Pharma Co Ltd's Cash Equivalents amounts to 2.7B JPY.

What is Fuji Pharma Co Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-10%

Over the last year, the Cash Equivalents growth was -32%. The average annual Cash Equivalents growth rates for Fuji Pharma Co Ltd have been -34% over the past three years , -18% over the past five years , and -10% over the past ten years .

Back to Top